
High-Dose GLP-1 Drugs May Dim Joy, Doctors Warn
Doctors report three cases of anhedonia (loss of pleasure) in people taking the obese‑treating GLP-1 drug tirzepatide at very high doses (up to 15 mg/week). In all cases, symptoms eased after reducing the dose (and in one case adding an antidepressant), suggesting the effect is dose-related and manageable. The side effect is linked to GLP-1s’ influence on brain reward regions like the ventral tegmental area, though GLP-1 therapies remain associated with reduced depression symptoms overall. Clinicians emphasize monitoring motivation and pleasure during treatment, especially at higher doses, and note that this should not deter indicated use for obesity or type 2 diabetes while remaining vigilant and adjusting dosing as needed.













